Flu vaccine offered poor protection for seniors this year, CDC says

Share this article:

This season's influenza vaccine was largely ineffective for seniors, according to Centers for Disease Control and Prevention numbers released Thursday.

The flu vaccine was effective for only 9% of those 65 and older, as measured by a survey of nearly 2,700 adults and children undertaken between Dec. 3 and Jan. 19. This means the vaccine prevented a “statistically insignificant” number of seniors from needing outpatient medical attention for the flu, according to the CDC. Overall, the shot was 56% effective for all age groups over six months old.

Seniors generally are more severely affected by the flu and often are less responsive to vaccines than younger people. However, the flu-related death rate for seniors reached extremely high levels this year. The vaccine may have been ineffective because seniors did not respond to its influenza A (H3N2) component, the CDC stated. The vaccine was 67% effective in protecting seniors against influenza B.

The findings are interim, and the CDC plans further research to see if chronic medical conditions or other factors played a part in the vaccine's ineffectiveness among seniors. The flu shot's effectiveness has varied from year to year, so these findings should not be seen as discrediting the need for the vaccine, CDC officials stressed.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.